{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"16.7","upperLimit":"25.8","value":"21.2"},{"groupId":"OG001","lowerLimit":"24.9","upperLimit":"31.3","value":"28.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"264"},{"groupId":"OG001","value":"345"}],"units":"Participants"}],"description":"Duration of response (DOR) was calculated for participants who achieved a best response of stringent complete response (sCR), complete response (CR), very good partial response (VGPR), or partial response (PR). Duration of response was defined as the time in months from the initial start of response (PR or better) to the earlier of documented progressive disease (PD) or death due to any cause. Participants who had not progressed or died were censored according to the censoring rules defined previously for PFS.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received their randomized study treatment in 28-day cycles until disease progression or unacceptable toxicity. Lenalidomide 25 mg was administered orally on days 1 to 21 and dexamethasone 40 mg was administered orally or intravenously on days 1, 8, 15, and 22.","id":"OG000","title":"Lenalidomide and Dexamethasone (Rd)"},{"description":"Participants received their randomized study treatment in 28-day cycles until disease progression or unacceptable toxicity. Carfilzomib 20 mg/m² was administered intravenously (IV) on days 1 and 2 of cycle 1, then escalated to 27 mg/m² on Days 8, 9, 15, and 16 of cycle 1 and continuing on days 1, 2, 8, 9, 15, and 16 of cycle 2 through cycle 12 and then from cycle 13 through cycle 18, 27 mg/m² on days 1, 2, 15, and 16. Lenalidomide 25 mg was administered orally on days 1 to 21 of every cycle. Dexamethasone 40 mg was administered orally or IV on days 1, 8, 15, and 22 of every cycle.","id":"OG001","title":"Carfilzomib, Lenalidomide, and Dexamethasone (CRd)"}],"paramType":"MEDIAN","populationDescription":"The Intent to treat (ITT) population with participantant who achieved a best overall response of PR or better.","reportingStatus":"POSTED","timeFrame":"From randomization through the data cutoff date of 16 June 2014. Longest follow-up time was approximately 42 months.","title":"Duration of Response","type":"SECONDARY","unitOfMeasure":"months"}